The Cancer Therapeutics Program membership includes clinical and basic science researchers whose shared focus is the translation of novel cancer therapies into new standards of care. This includes introduction of novel therapies developed in laboratories within the Abramson Cancer Center. In the period of the current report there has also been an initiative taken with one company (Pfizer) through which Penn investigators have obtained access to selected Pfizer compounds to pursue avenues of mutual interest that would not ordinarily rise to the priority within the company of receiving industry funding. Through this mechanism, the unexpected activity of an activating antibody directed to CD40 in pancreatic cancer has been discovered, as well as activity of a cdk 4/6-directed cell cycle inhibitor in two malignancies. The success of this collaboration is a constructive start to developing models for the optimal interaction of industry and academia in a time of intense scrutiny. For novel therapies that originate from industry sources in general, priority has been placed on the development of therapies for which Program members have scientific expertise regarding the pathways being perturbed or a research interest in defining responsive and refractory subpopulations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-37
Application #
8567184
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$130,182
Indirect Cost
$90,210
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Taylor, Laura A; Abraham, Ronnie M; Tahirovic, Emin et al. (2017) High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Mod Pathol 30:634-639
Rebecca, Vito W; Nicastri, Michael C; McLaughlin, Noel et al. (2017) A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discov 7:1266-1283
Till, Jacob E; Yoon, Changhwan; Kim, Bang-Jin et al. (2017) Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression. Cancer Res 77:5349-5359
Ewens, Kathryn G; Bhatti, Tricia R; Moran, Kimberly A et al. (2017) Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma. Cancer Med 6:619-630
Chee, Wonshik; Lee, Yaelim; Im, Eun-Ok et al. (2017) A culturally tailored Internet cancer support group for Asian American breast cancer survivors: A randomized controlled pilot intervention study. J Telemed Telecare 23:618-626
Zang, Tianzhu; Taplin, Mary-Ellen; Tamae, Daniel et al. (2017) Testicular vs adrenal sources of hydroxy-androgens in prostate cancer. Endocr Relat Cancer 24:393-404
Walter, David M; Venancio, Olivia S; Buza, Elizabeth L et al. (2017) Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma. Cancer Res 77:1719-1729
Carrer, Alessandro; Parris, Joshua L D; Trefely, Sophie et al. (2017) Impact of a High-fat Diet on Tissue Acyl-CoA and Histone Acetylation Levels. J Biol Chem 292:3312-3322
Fennelly, Colin; Amaravadi, Ravi K (2017) Lysosomal Biology in Cancer. Methods Mol Biol 1594:293-308
Safo, Sandra E; Li, Shuzhao; Long, Qi (2017) Integrative analysis of transcriptomic and metabolomic data via sparse canonical correlation analysis with incorporation of biological information. Biometrics :

Showing the most recent 10 out of 955 publications